RESULTS
Examination of baseline hsCRP levels revealed that 49 individuals (35%) exhibited normal levels, 51 individuals (36%) exhibited mildly elevated levels, and 40 individuals (29%) exhibited moderately elevated levels. There were no baseline differences in hsCRP levels between treatment groups (Baseline demographic, clinical, and neurocognitive characteristics of the sample by CRP levels and treatment group. Scores within cognitive domains reflect global, mean‐rank scores where higher performance is consistent with better performance relative to other trial participantsOmnibus test for differences between CRP groups: **